A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
Launched by ASTRAZENECA · Sep 9, 2005
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).
- • Fasting glucose (FG) \< - 240 mg/dL, while on metformin or antidiabetic diet alone.
- • HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%
- Exclusion Criteria:
- • Women of childbearing potential
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Orlando, Florida, United States
Fort Lauderdale, Florida, United States
Miami, Florida, United States
New Orleans, Louisiana, United States
Patients applied
Trial Officials
Bristol Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials